An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Insulet Corporation (NASDAQ: PODD) will announce its third quarter 2022 financial results on November 3, 2022, after market close. A conference call will follow at 4:30 p.m. ET. The call will be accessible on the Company’s Investor Relations website. Insulet's Omnipod product platform offers a unique, tubeless insulin delivery system that simplifies diabetes management, with the latest version, the Omnipod® 5, designed for automated insulin delivery integrated with a continuous glucose monitor.
Positive
Launch of Omnipod® 5 Automated Insulin Delivery System enhances product offerings.
Strong focus on innovation aimed at simplifying diabetes management.
Negative
None.
ACTON, Mass.--(BUSINESS WIRE)--
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2022 on November 3, 2022 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).
The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, “Events and Presentations,” and will be archived for future replay. To participate in the live call via phone, please pre-register online here to receive a telephone number and a unique passcode required to enter the call.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.